Extended Data Fig. 2: ERX-41 has no observed toxicity in vivo.
Nude mice with MDA-MB-231 xenograft tumors were treated with either a vehicle or ERX-41 (10 mg/kg/day) for a duration of 52 days. Similarly, BALB/c mice with D2A1 xenograft tumors received a treatment of 20 mg/kg/day for 23 days. Following these treatments, histologic architecture in various organs of both the nude mice and BALB/c mice was assessed using H&E staining (a). The uteri in these mice were also evaluated for changes in their proliferation index (ki67 staining (b, with quantitation. Data are presented as mean ± SEM, n = 4 fields for all groups except the ‘ERX-41’ group in D2A1 mice, whose n = 5 fields. Significance was determined by unpaired two tailed Student’s t-test)), or endometrial cell height (c, with quantitation. Data are presented as mean ± SEM, n = 4 fields for ‘Vehicle’ group, n = 5 fields for ‘ERX-41’ group. Significance was determined by unpaired two tailed Student’s t-test), or ERα expression (d). e-f: Evaluation of the effect of daily administration of oral ERX-41 (10 mg/kg/day) for 10 days on the distribution of plasma cells in the bone marrow by flow cytometry (e, Data are presented as mean ± SEM, n = 4 mice. Significance was determined by unpaired two tailed Student’s t-test) and antibody-secreting cells (ASCs) that produces IgM or IgG in the bone marrow using ELISPOT analysis (f, Data are presented as mean ± SEM, n = 8 samples from 4 mice. Significance was determined by unpaired two tailed Student’s t-test) with quantitation. The experiments in a and d were done once. Numerical source data for b, c, e and f are provided.
